Amendments to the Claims

Please cancel Claims 98-163. Please amend Claims 1, 2, 8-15, 17, 18, 20, 25-31, 33, 34, 36, 39-46, 48, 49, 51, 54-60, 62, 63, 65, 70-77, 79, 80, 82, 87-93, 95, and 96. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of inhibiting the interaction of a cell bearing mammalian CC- chemokine receptor 1 (CCR1) with a ligand thereof, comprising contacting said cell with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) or portion of said receptor comprising the second extracellular loop and inhibits binding of said ligand to the receptor, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.

2. (Currently Amended) A method according to Claim 1, wherein the cell is selected from the group consisting of lymphocytes, monocytes, granulocytes, neutrophils, T cells, basophils, and cells comprising a recombinant nucleic acid encoding CCR1 or a portion thereof comprising the second extracellular loop.

3. (Original) A method according to Claim 2, wherein the cell is a T cell selected from the group consisting of CD26+ cells and CD45RO+ cells.

4. (Original) A method according to Claim 1, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.

5. (Original) A method according to Claim 1, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.

6. (Original) A method according to Claim 1, wherein the ligand is a chemokine.

7. (Original) A method according to Claim 6, wherein the chemokine is any one or more of MIP-1α, RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 or MPIF.

8. (Currently Amended) A method according to Claim 1, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of:

a) monoclonal antibody 2D4;

b) antigen-binding fragments of (a) which bind to mammalian CC-chemokine receptor 1 (CCR1) or a portion thereof comprising the second extracellular loop; and

c) combinations of the foregoing.

9. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.

10. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.

11. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

12. (Currently Amended) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

13. (Currently Amended) A method according to Claim 12, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

14. (Currently Amended) A method according to Claim 12, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

15. (Currently Amended) A method according to Claim 14, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

16. (Original) A method according to Claim 1, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.

17. (Currently Amended) A method according to Claim 16, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

18. (Currently Amended) A method according to Claim 17, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

19. (Original) A method according to Claim 1, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

20. (Currently Amended) A method of inhibiting the interaction of a cell bearing mammalian CC- chemokine receptor 1 (CCR1) with a ligand thereof, comprising contacting said cell with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) ~~or portion of said receptor~~ and inhibits binding of said ligand to the receptor, wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.

21. (Original) A method according to Claim 20, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.

22. (Original) A method according to Claim 20, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.

23. (Original) A method according to Claim 20, wherein the ligand is a chemokine.

24. (Original) A method according to Claim 23, wherein the chemokine is selected from the group consisting of MIP-1α, RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 and MPIF.

25. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.

26. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.

27. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

28. (Currently Amended) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

29. (Currently Amended) A method according to Claim 28, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

30. (Currently Amended) A method according to Claim 28, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

31. (Currently Amended) A method according to Claim 30, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

32. (Original) A method according to Claim 20, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.

33. (Currently Amended) A method according to Claim 32, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

34. (Currently Amended) A method according to Claim 33, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

35. (Original) A method according to Claim 20, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

36. (Currently Amended) A method of inhibiting a function associated with binding of a chemokine to a mammalian CC-chemokine receptor 1 (CCR1) or a functional portion of said receptor, comprising contacting a composition comprising the receptor or functional portion ~~thereof~~ with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or portion of said receptor comprising the second extracellular loop, wherein said antibody or fragment inhibits binding of said chemokine to mammalian CC-chemokine receptor 1 (CCR1) and

inhibits one or more functions associated with binding of the chemokine to the receptor, and wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.

37. (Original) A method according to Claim 36, wherein the chemokine is any one or more of MIP-1α, RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 or MPIF.

38. (Original) A method according to Claim 36, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.

39. (Currently Amended) A method according to Claim 36, wherein the antibody or antigen-binding fragment is selected from the group consisting of:

a) monoclonal antibody 2D4;

b) antigen-binding fragments of (a) which bind to mammalian CC-chemokine receptor 1 (CCR1) or a portion thereof comprising the second extracellular loop; and

c) combinations of the foregoing.

40. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.

41. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.

42. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

43. (Currently Amended) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

44. (Currently Amended) A method according to Claim 43, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

45. (Currently Amended) A method according to Claim 43, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

46. (Currently Amended) A method according to Claim 45, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

47. (Original) A method according to Claim 36, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.

48. (Currently Amended) A method according to Claim 47, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

49. (Currently Amended) A method according to Claim 48, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

50. (Original) A method according to Claim 36, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

51. (Currently Amended) A method of inhibiting a function associated with binding of a chemokine to a mammalian CC-chemokine receptor 1 (CCR1) or a functional portion of said receptor, comprising contacting a composition comprising the receptor or functional

portion ~~thereof~~ with ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) ~~or portion of said receptor~~, wherein said antibody or fragment inhibits binding of said chemokine to mammalian CC-chemokine receptor 1 (CCR1) and inhibits one or more functions associated with binding of the chemokine to the receptor, and wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.

52. (Original) A method according to Claim 51, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.

53. (Original) A method according to Claim 51, wherein the chemokine is selected from the group consisting of MIP-1α, RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 and MPIF.

54. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.

55. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.

56. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

57. (Currently Amended) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

58. (Currently Amended) A method according to Claim 57, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

59. (Currently Amended) A method according to Claim 57, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

60. (Currently Amended) A method according to Claim 59, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

61. (Original) A method according to Claim 51, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.

62. (Currently Amended) A method according to Claim 61, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

63. (Currently Amended) A method according to Claim 62, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

64. (Original) A method according to Claim 51, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

65. (Currently Amended) A method of inhibiting leukocyte trafficking in a patient, comprising administering to the patient a composition comprising ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or portion of said receptor comprising the second extracellular loop and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.

66. (Original) A method according to Claim 65, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.

67. (Original) A method according to Claim 65, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.

68. (Original) A method according to Claim 65, wherein the ligand is a chemokine.

69. (Original) A method according to Claim 68, wherein the chemokine is any one or more of MIP-1α, RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 or MPIF.

70. (Currently Amended) A method according to Claim 65, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of:

a) monoclonal antibody 2D4;

b) antigen-binding fragments of (a) which bind to mammalian CC-chemokine receptor 1 (CCR1) or a portion thereof comprising the second extracellular loop; and

c) combinations of the foregoing.

71. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.

72. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.

73. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

74. (Currently Amended) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

75. (Currently Amended) A method according to Claim 74, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

76. (Currently Amended) A method according to Claim 74, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

77. (Currently Amended) A method according to Claim 76, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

78. (Original) A method according to Claim 65, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.

79. (Currently Amended) A method according to Claim 78, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

80. (Currently Amended) A method according to Claim 79, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

81. (Original) A method according to Claim 65, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

82. (Currently Amended) A method of inhibiting leukocyte trafficking in a patient, comprising administering to the patient a composition comprising ~~an effective amount of~~ an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) ~~or portion of said receptor~~ and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.

83. (Original) A method according to Claim 82, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.

84. (Original) A method according to Claim 82, wherein said mammalian CC-chemokine receptor 1 is a human CC-chemokine receptor 1.

85. (Original) A method according to Claim 82, wherein the ligand is a chemokine.

86. (Original) A method according to Claim 85, wherein the chemokine is selected from the group consisting of MIP-1α, RANTES, MCP-2, MCP-3, leukotactin-1, HCC-1 and MPIF.

87. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.

88. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.

89. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.

90. (Currently Amended) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

91. (Currently Amended) A method according to Claim 90, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 2D4.

92. (Currently Amended) A method according to Claim 90, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

93. (Currently Amended) A method according to Claim 92, wherein said humanized antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

94. (Original) A method according to Claim 82, wherein said antibody or antigen-binding fragment is a recombinant antibody or antigen-binding fragment thereof.

95. (Currently Amended) A method according to Claim 94, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.

96. (Currently Amended) A method according to Claim 95, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 2D4.

97. (Original) A method according to Claim 82, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an $F(ab')_2$ fragment.

Claims 98-163 (Cancelled)